These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842 [TBL] [Abstract][Full Text] [Related]
3. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. Roberts P; Mittermueller TJ; Montuoro A; Sulzbacher F; Munk M; Sacu S; Schmidt-Erfurth U Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6623-30. PubMed ID: 25190663 [TBL] [Abstract][Full Text] [Related]
4. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732 [TBL] [Abstract][Full Text] [Related]
5. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S; Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928 [TBL] [Abstract][Full Text] [Related]
6. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Gupta B; Adewoyin T; Patel SK; Sivaprasad S Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484 [TBL] [Abstract][Full Text] [Related]
7. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O Retina; 2011; 31(7):1261-7. PubMed ID: 21499194 [TBL] [Abstract][Full Text] [Related]
8. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Pushpoth S; Sykakis E; Merchant K; Browning AC; Gupta R; Talks SJ Br J Ophthalmol; 2012 Dec; 96(12):1469-73. PubMed ID: 23001255 [TBL] [Abstract][Full Text] [Related]